drugset
drugset / Trial / NCT06735248

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ↗

Phase 2 Recruiting 180 enrolled ModernaTX, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

Timeline

Start
2025-04-16
Primary completion
2029-01-08
Completion
2029-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1195 Vaccine — Intramuscular

Indications

multiple sclerosis